Article Text
PDF
Abstract
Objective To evaluate patient exposure to radiation during common interventional neuroradiology procedures performed with a recent Flat Panel Detector (FPD) angiographic system and compare to recently published values.
Method All consecutive patients from February 2015 to November 2015, who underwent cerebral diagnostic angiogram or Intervention, including embolization of arteriovenous fistula, arteriovenous malformation, aneurysms, stroke mechanical thrombectomy and other types of interventional procedures, on two modern FPD angiographic biplane systems (Innova IGS 630, GE Healthcare, Chalfont St Giles, UK), were retrospectively analyzed. Dose-area product (DAP), cumulated Air Kerma (CAK) per plane, fluoroscopic time (FT) and total number of Digital Subtracted Angiography (DSA) frames were collected and analyzed for each category. Results are expressed as median (interquartile range). The data was compared with previously published literature on other modern FPD systems only.
Results 755 consecutive cases were performed in our institution, including 398 cerebral angiograms, 33 AVF/AVM embolizations, 71 aneurysm embolizations, 73 mechanical thrombectomies and 180 Other Interventions.
The DAP (Gy.cm²), Fontal and Lateral CAK (Gy), FT (min) and total number of DSA frames were as follows: 43 (33–60), 0.26 (0.19–0.33), 0.09 (0.07–0.13), 5.6 (4.2–7.5), 245 (193–314) for Cerebral Diagnostic and 66 (41–110), 0.46 (0.25–0.80), 0.18 (0.10–0.30), 18.3 (9.1–30.2), 281 (184–427) when combining all interventional cases.
Radiation data is summarized in Table 1, as well as published reference levels.
Conclusion Our diagnostic group had a lower median and in the 75 th percentile of DAP and fluoroscopy time, when compared with published literature, with the number of DSA frames comparable.
In our intervention group, both DAP and number of DSA frames were significantly lower than values reported in the literature, despite a higher fluoro time. The sub-group analysis by procedure type also revealed a lower or comparable DAP.
Disclosures A. Hassan: 2; C; GE Healthcare. S. Amelot: 5; C; GE Healthcare.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/